Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy

Steroids

Volumn 76, Issue 8, 2011, Pages 792-796

  Nair, Hareesh B ^a   Kirma, Nameer B ^a   Ganapathy, Manonmani ^a   Vadlamudi, Ratna K ^a   Tekmal, Rajeshwar Rao ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Combination therapy; Drug resistance; Estrogen receptor beta agonists

Indexed keywords

CYCLIN D1; DIARYLPROPIONITRILE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P27;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHEMOSENSITIZATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION REGULATION; HORMONE RECEPTOR INTERACTION; HORMONE RESISTANCE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MICE; MICE, NUDE; NITRILES; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 79958768946     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.038     Document Type: Conference Paper

References (27)

1. Tekmal RR, Liu YG, Nair HB, Jones J, Perla RP, Lubahn DB, et al. Estrogen receptor alpha is required for mammary development and the induction of mammary hyperplasia and epigenetic alterations in the aromatase transgenic mice. J Steroid Biochem Mol Biol 2005;95:9-15. (Pubitemid 41137288)
2. Mueller SO, Clark JA, Myers PH, Korach KS. Mammary gland development in adult mice requires epithelial and stromal estrogen receptor alpha. Endocrinology 2002;143:2357-65. (Pubitemid 34521582)
3. Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009;30:343-75.
4. Macedo LF, Sabnis G, Brodie A. Aromatase inhibitors and breast cancer. Ann N Y Acad Sci 2009;1155:162-73.
5. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 2004;9(Suppl. 3):20-6. (Pubitemid 38747836)
6. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35. (Pubitemid 38868139)
7. Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K, et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A 2002;99:15578-83. (Pubitemid 35407484)
8. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006;66:11207-13. (Pubitemid 46009948)
9. Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 2008;109:241-50. (Pubitemid 351644839)
10. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001;142: 4120-30. (Pubitemid 32802685)
11. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR, Hanby AM. Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 2004;5:174-81. (Pubitemid 38262850)
12. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 2004;101:1566-71. (Pubitemid 38236167)
13. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004;64:423-8. (Pubitemid 38114127)
14. Harris HA. Estrogen receptor-{beta}: recent lessons from in vivo studies. Mol Endocrinol 2006.
15. Veeneman GH. Non-steroidal subtype selective estrogens. Curr Med Chem 2005;12:1077-136. (Pubitemid 40674196)
16. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, et al. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 2000;43:4934-47. (Pubitemid 32040974)
17. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 1999;140:800-4. (Pubitemid 29058215)
18. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001;44:4230-51. (Pubitemid 33095330)
19. Tekmal RR, Nair HB, Perla RP, Kirma N. HER-2/neuxaromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis. J Steroid Biochem Mol Biol 2007;106:111-8. (Pubitemid 47362657)
20. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010;79:330-8.
21. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949-54. (Pubitemid 20361096)
22. Brodie A, Sabnis G, Macedo L. Xenograft models for aromatase inhibitor studies. J Steroid Biochem Mol Biol 2007;106:119-24. (Pubitemid 47362656)
23. Liu YG, Tekmal RR, Binkley PA, Nair HB, Schenken RS, Kirma NB. Induction of endometrial epithelial cell invasion and c-fms expression by transforming growth factor beta. Mol Hum Reprod 2009;15:665-73.
24. Sanchez-Munoz A, Ribelles N, Alba E. Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question? Clin Transl Oncol 2010;12:614-20.
25. Soldati R, Wargon V, Cerliani JP, Giulianelli S, Vanzulli SI, Gorostiaga MA, et al. Inhibition of mammary tumor growth by estrogens: is there a specific role for estrogen receptors alpha and beta? Breast Cancer Res Treat 2011;123:709-24.
26. Sabnis G, Brodie A. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Clin Breast Cancer 2010;10:E6-15.
27. Smollich M, Gotte M, Fischgrabe J, Macedo LF, Brodie A, Chen S, et al. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Res Treat 2010;123:345-57.